These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30508889)

  • 1. A multi-facet comparative analysis of neuromyelitis optica spectrum disorders in patients with seropositive and seronegative AQP4-IgG.
    Wang X; Chen X; Zhu C; Ma H; Wang F; Qin L; Li W
    Medicine (Baltimore); 2018 Nov; 97(48):e13100. PubMed ID: 30508889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
    van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
    Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
    Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
    JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
    Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
    Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders.
    Yick LW; Tang CH; Ma OK; Kwan JS; Chan KH
    J Neuroinflammation; 2020 Aug; 17(1):236. PubMed ID: 32782018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of serostatus in pediatric neuromyelitis optica spectrum disorders: A nationwide multicentric study.
    Solmaz I; Öncel IH; Konuşkan B; Erol I; Orgun LT; Yılmaz Ü; Ünalp A; Atasoy E; Aksoy E; Yılmaz D; Öztürk M; Karaca NB; Yılmaz S; Yiş U; Dündar NO; Parlak Ş; Vural A; Günbey C; Anlar B
    Mult Scler Relat Disord; 2023 Sep; 77():104847. PubMed ID: 37393803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort.
    Castro-Suarez S; Guevara-Silva E; Osorio-Marcatinco V; Alvarez-Toledo K; Meza-Vega M; Caparó-Zamalloa C
    Mult Scler Relat Disord; 2022 Aug; 64():103919. PubMed ID: 35691236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of Aquaporin-4 Immunoglobulin G in Longitudinally Extensive Transverse Myelitis With Antiphospholipid Antibodies.
    Guerra H; Pittock SJ; Moder KG; Fryer JP; Gadoth A; Flanagan EP
    Mayo Clin Proc; 2018 Sep; 93(9):1299-1304. PubMed ID: 29655487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.
    Jarius S; Ruprecht K; Wildemann B; Kuempfel T; Ringelstein M; Geis C; Kleiter I; Kleinschnitz C; Berthele A; Brettschneider J; Hellwig K; Hemmer B; Linker RA; Lauda F; Mayer CA; Tumani H; Melms A; Trebst C; Stangel M; Marziniak M; Hoffmann F; Schippling S; Faiss JH; Neuhaus O; Ettrich B; Zentner C; Guthke K; Hofstadt-van Oy U; Reuss R; Pellkofer H; Ziemann U; Kern P; Wandinger KP; Bergh FT; Boettcher T; Langel S; Liebetrau M; Rommer PS; Niehaus S; Münch C; Winkelmann A; Zettl U UK; Metz I; Veauthier C; Sieb JP; Wilke C; Hartung HP; Aktas O; Paul F
    J Neuroinflammation; 2012 Jan; 9():14. PubMed ID: 22260418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review.
    Tao S; Zhang Y; Ye H; Guo D
    Mult Scler Relat Disord; 2019 Oct; 35():185-192. PubMed ID: 31398657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABCB1 gene polymorphisms impact the effect of high-dose intravenous methylprednisolone therapy on optic neuritis associated with AQP4-IgG-positive neuromyelitis optica spectrum disorder.
    Dai Y; Ni S; Wu F; Guo S; Zhao X; Wang J
    J Clin Pharm Ther; 2022 Sep; 47(9):1379-1387. PubMed ID: 35488449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different alteration patterns of sub-macular choroidal thicknesses in aquaporin-4 immunoglobulin G antibodies sero-positive neuromyelitis optica spectrum diseases and isolated optic neuritis.
    Peng C; Li L; Yang M; Teng D; Wang J; Lai M; Qian H; Li H; Zhou H; Xu Q; Wei S
    Acta Ophthalmol; 2020 Dec; 98(8):808-815. PubMed ID: 32657009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and demographic characteristics of patients with NMOSD: a longitudinal retrospective analysis of a Slovak cohort of 63 patients.
    Szilasiová J; Gazda J; Mikula P; Cvengrošová A; Fedičová M; Hančinová V; Kantorová E; Karlík M; Kováčová S
    Neurol Sci; 2024 Feb; 45(2):693-698. PubMed ID: 37698786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders.
    Tzartos JS; Stergiou C; Kilidireas K; Zisimopoulou P; Thomaidis T; Tzartos SJ
    PLoS One; 2013; 8(9):e74773. PubMed ID: 24086369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients.
    Hamid SHM; Whittam D; Mutch K; Linaker S; Solomon T; Das K; Bhojak M; Jacob A
    J Neurol; 2017 Oct; 264(10):2088-2094. PubMed ID: 28840314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.